Sebastian Ewen1*, MD; Melvin D. Lobo2, MD; Atul Pathak3, MD; Roland E. Schmieder4, MD; Costas Tsioufis5, MD; William Wijns6,7, MD; Felix Mahfoud1, MD
1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 2. William Harvey Research Institute and Barts NIHR Cardiovascular Biomedical Research Unit, Queen Ma
Introduction to the session
The aim of the summary report is to capture the session at EuroPCR 2016 that reviewed the implications for clinical practice of SPRINT (Systolic Blood Pressure Intervention Trial)1, in order to share the critical analysis of the trial and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.
SPRINT certainly addresses a clinically relevant problem in attempting to improve the definition of optimal targets for systolic blood pressure (SBP) lowering in a hypertensive population at varying levels of cardiovascular risk. However, ...